ArticleFrontiers in oncology2026
A ferroptosis-related lncRNAs risk score model identifies LINC02178 as a potential regulator of ferroptosis sensitivity in cervical cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer remains a major global health burden among women. Persistent infection with high-risk human papillomavirus (HR-HPV) is the primary driver of cervical carcinogenesis, yet additional cellular regulatory processes are required for tumor progression. Ferroptosis, an iron-dependent form of regulated cell death, has been implicated in cancer metabolism and therapeutic response. However, the involvement of ferroptosis-related long non-coding RNAs (FRLs) in human papillomavirus (HPV)-associated cervical cancer remains insufficiently understood. Methods: Transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and UCSC Xena were analyzed to identify FRLs. A prognostic risk-scoring model (RSM) was constructed using LASSO Cox regression and evaluated by survival analysis and time-dependent receiver operating characteristic (ROC) curves. Expression patterns of selected FRLs were further examined in cervical swab samples with different HPV infection subtypes using quantitative polymerase chain reaction (qPCR). Functional validation was performed in HPV16-positive SiHa cells following small interfering RNA (siRNA)-mediated knockdown of LINC02178, combined with ferroptosis modulation using Erastin or Ferrostatin-1. Cell viability, migration, and ferroptosis-associated biochemical indicators were assessed. Results: A prognostic model based on 22 FRLs showed stable predictive performance and remained an independent prognostic factor after adjustment for clinical variables. Among these FRLs, LINC02178 emerged as a standout risk factor, exhibiting markedly elevated expression in HPV16-positive tissues and a strong positive correlation with the lipid droplet-associated protein PLIN2-suggesting a potential role in lipid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.